Cemtrex gets Nasdaq extension to Feb 17, 2025 to cure equity deficiency

CEMTREX INC

Nasdaq granted extension for minimum $2.5M stockholders' equity compliance.
Company must complete financing by Feb 17, 2025 and evidence compliance.
Plans include exercising ~$10M in warrant liabilities and converting ~$12M debt to equity.
Projected equity of $10M by Dec 31, 2024 per company submission.
Failure to evidence compliance by March 31, 2025 periodic filing may lead to delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.